Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.
Actively Recruiting
Researchers are evaluating RAY121, an inhibitor of the classical complement pathway, in a Phase 1b basket trial involving patients with various immunological diseases including antiphospholipid syndrome, bullous pemphigoid, Behets syndrome, dermatomyositis, immune-mediated necrotizing myopathy, and immune thrombocytopenia. This study aims to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of multiple doses of RAY121 in these patient populations. All enrolled patients will receive multiple doses of RAY121 administered by injection. The study is designed as a single-group trial where participants receive the experimental treatment without comparison to placebo or other interventions. Treatment monitoring and assessments will continue up to 32 weeks following the baseline visit to evaluate the effects and behavior of the drug in the body. Participants will be involved in regular assessments including monitoring for adverse events, measurement of drug concentration and activity, complement pathway activity, and antibody formation against RAY121 from baseline through week 32. The study includes safety evaluations and collection of pharmacokinetic and pharmacodynamic data to understand how the drug works and is tolerated over time. The total participation duration may last up to 32 weeks with ongoing monitoring throughout this period.